RecruitingPhase 1Phase 2NCT04892251

Ketamine Assisted Psychotherapy for Opioid Use Disorder

Sponsor

University of Utah

Enrollment

60 participants

Start Date

May 20, 2021

Study Type

INTERVENTIONAL

Conditions

Opioid-use Disorder

Summary

This pilot clinical trial aims to assess the preliminary efficacy of ketamine as an adjunct for a mindfulness-based intervention for opioid use disorder.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called MORE and MORE+KAP for people with opioid-use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTMORE+KAP

Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly

BEHAVIORALMORE

Mindfulness-Oriented Recovery Enhancement

Locations(1)

Center on Mindfulness and Integrative Health Intervention Development

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04892251

Related Trials

Identifying Biomarkers Related to Opioid Use and Pain Response Following Traumatic Injury and Surgery

NCT076932701 location

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT066511779 locations